Ankündigung • Jul 03
AbbVie Inc. (NYSE : ABBV) completed the acquisition of Device manufacturing facility in Tempe, Arizona from West Pharmaceutical Services, Inc. (NYSE : WST). AbbVie Inc. (NYSE : ABBV) entered into a definitive agreement to acquire Device manufacturing facility in Tempe, Arizona from West Pharmaceutical Services, Inc. (NYSE : WST) for approximately $110 million on January 12, 2026. The transaction includes the transfer of manufacturing facilities, including multiple production lines, and 3.5 mL on-body injector technology to support production of current and next-generation AbbVie immunology and neuroscience medicines. Upon completion, the acquisition will significantly expand AbbVie's presence and economic impact in Arizona.
The transaction is anticipated to close in mid-2026, subject to closing conditions.
Demetra Karamanos and Julia Feldman of Jones Day acted as a legal advisor for West Pharmaceutical Services, Inc. (NYSE:WST)
AbbVie Inc. (NYSE : ABBV) completed the acquisition of Device manufacturing facility in Tempe, Arizona from West Pharmaceutical Services, Inc. (NYSE : WST) on July 1, 2026 Live-Nachrichten • Jul 02
West Pharmaceutical Services Completes Sale of SmartDose 3.5mL Manufacturing and Supply Rights West Pharmaceutical Services completed the sale and transfer of the manufacturing and supply rights, along with associated facilities, for its SmartDose 3.5mL On-Body Delivery System on 1 July 2026, with the transaction closing as planned.
The shift out of the 3.5mL SmartDose line, while continuing to develop and manufacture other SmartDose versions, including the 10mL system for larger volume delivery, alters West’s product mix and manufacturing footprint and signals a tighter focus on selected delivery formats.
West Pharmaceutical’s stock trades at about $365.00, with a 90‑day return of 43.2%, reflecting strong recent momentum in the share price.
This transaction concentrates West Pharmaceutical Services more heavily on its remaining SmartDose platforms, which could affect future revenue composition and capital allocation, while also introducing execution risk around scaling the 10mL system and managing any transition for existing 3.5mL customers. Live-Nachrichten • Jun 23
West Pharmaceutical Services Lifts 2026 Outlook After Biologics Revenue Jumps Past Forecasts West Pharmaceutical Services reported Q1 2026 revenue of $844.9m, up 21% year on year and about 8.4% above analyst expectations, and raised its full-year 2026 revenue and adjusted EPS guidance on the back of strong biologics growth.
Management highlighted particularly strong performance in High Value Products Components, with double-digit growth in GLP-1 and non-GLP-1 biologics, while also flagging potential capacity constraints and pricing pressure as areas to watch.
West Pharmaceutical Services shares trade around $329.71, with the stock up 34.4% over the past 90 days, materially ahead of the broader market over the same period.
The combination of raised guidance, strong biologics demand, and a sharp share price move concentrates attention on execution risks, particularly the company’s ability to add capacity and manage pricing without compressing margins. Live-Nachrichten • Jun 15
West Pharmaceutical Services Lifts 2026 Outlook After Q1 Growth Driven by Biologics and GLP-1 Demand West Pharmaceutical Services reported Q1 2026 revenue up 21.1% year over year, with organic growth of 15.3%, helped by high-value components tied to biologics and GLP-1 therapies.
Adjusted EPS for the quarter came in at $2.13, 27% above analyst expectations, and management raised full-year 2026 revenue guidance to a range of $3.295 billion to $3.35 billion and adjusted EPS guidance to a range of $8.40 to $8.75.
The company is exiting a legacy continuous glucose monitoring contract that is expected to create a $40 million revenue headwind in the second half, while also approving a new $1 billion share repurchase program and buying back 1.2 million shares in Q1.
The combination of higher guidance, GLP-1 and biologics demand, and active buybacks reflects a management team leaning into current momentum while also acknowledging a known contract headwind later in the year.
For investors, key questions include how durable GLP-1 and biologics-related demand will be and whether the exit from the CGM contract ultimately results in a cleaner long-term portfolio or becomes a drag if replacement revenue does not fully materialize. Live-Nachrichten • Jun 08
West Pharmaceutical Services Announces New CEO Board Changes and US$297 Million Share Buyback West Pharmaceutical Services appointed Michel Lagarde as President and CEO, effective August 31, 2026, with outgoing CEO Eric M. Green set to retire on the same date.
Lagarde will also join the Board of Directors, while Robert F. Friel has been elected as the new Board Chair.
The company reported recent share repurchases totaling US$297.65 million for 1.22 million shares and issued updated guidance for Q2 2026 net sales, which has been followed by higher price targets from several research firms.
This leadership transition, combined with active capital return through buybacks and refreshed sales guidance, indicates that the board is focused on continuity and capital allocation priorities.
For you as an investor, the key things to monitor are execution under the incoming CEO and how future guidance aligns with expectations that have informed the recent analyst target increases. Reported Earnings • Apr 26
First quarter 2026 earnings: EPS and revenues exceed analyst expectations First quarter 2026 results: EPS: US$1.93 (up from US$1.24 in 1Q 2025). Revenue: US$844.9m (up 21% from 1Q 2025). Net income: US$138.8m (up 55% from 1Q 2025). Profit margin: 16% (up from 13% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 8.4%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 5% per year. Upcoming Dividend • Apr 22
Upcoming dividend of US$0.22 per share Eligible shareholders must have bought the stock before 29 April 2026. Payment date: 06 May 2026. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of American dividend payers (4.2%). Lower than average of industry peers (0.6%). Ankündigung • Apr 09
West Pharmaceutical Services, Inc. to Report Q1, 2026 Results on Apr 23, 2026 West Pharmaceutical Services, Inc. announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on Apr 23, 2026 Ankündigung • Mar 13
West Pharmaceutical Services, Inc., Annual General Meeting, May 04, 2026 West Pharmaceutical Services, Inc., Annual General Meeting, May 04, 2026. Declared Dividend • Feb 20
Dividend of US$0.22 announced Shareholders will receive a dividend of US$0.22. Ex-date: 29th April 2026 Payment date: 6th May 2026 Dividend yield will be 0.4%, which is about the same as the industry average. Payout Ratios Payout ratio: 12%. Cash payout ratio: 14%. Reported Earnings • Feb 13
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: US$6.83 (up from US$6.75 in FY 2024). Revenue: US$3.07b (up 6.3% from FY 2024). Net income: US$493.7m (flat on FY 2024). Profit margin: 16% (in line with FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.3%. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 7% per year. Ankündigung • Feb 12
West Pharmaceutical Services, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2026 West Pharmaceutical Services, Inc. provided first quarter and full year 2026 guidance. First-quarter 2026 net sales are expected to be in the range of $770 million to $790 million, representing reported growth of 10.3% to 13.2% and organic growth of 4.6% to 7.4%.
Full-year 2026 net sales are expected to be in a range of $3.215 billion to $3.275 billion, which assumes a mid-year 2026 close for the sale of SmartDose 3.5ml to AbbVie. Reported growth is expected to be between 4.6% and 6.5% while organic net sales growth is expected to be approximately 5% to 7%. Net sales guidance includes an estimated full-year 2026 benefit of 2 percentage points based on current foreign currency exchange rates. Ankündigung • Jan 29
West Pharmaceutical Services, Inc. to Report Q4, 2025 Results on Feb 12, 2026 West Pharmaceutical Services, Inc. announced that they will report Q4, 2025 results Pre-Market on Feb 12, 2026 Upcoming Dividend • Jan 21
Upcoming dividend of US$0.22 per share Eligible shareholders must have bought the stock before 28 January 2026. Payment date: 04 February 2026. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of American dividend payers (4.3%). In line with average of industry peers (0.5%). Declared Dividend • Dec 12
Dividend of US$0.22 announced Shareholders will receive a dividend of US$0.22. Ex-date: 28th January 2026 Payment date: 4th February 2026 Dividend yield will be 0.3%, which is about the same as the industry average. Payout Ratios Payout ratio: 12%. Cash payout ratio: 17%. Ankündigung • Dec 10
West Pharmaceutical Services, Inc. Declares Regular Quarterly Dividend on Common Stock, Payable on February 4, 2026 On December 9, 2025, the board of directors of West Pharmaceutical Services, Inc. declared its regular quarterly dividend of $0.22 per share on the Company's common stock. The dividend is payable on February 4, 2026, to shareholders of record on January 28, 2026. Upcoming Dividend • Nov 05
Upcoming dividend of US$0.22 per share Eligible shareholders must have bought the stock before 12 November 2025. Payment date: 19 November 2025. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of American dividend payers (4.6%). Lower than average of industry peers (0.5%). Ankündigung • Oct 27
West Pharmaceutical Services, Inc. Announces the Launch of its West Synchrony Prefillable Syringe (PFS) System at CPHI Worldwide in Frankfurt, Germany West Pharmaceutical Services, Inc. announced the launch of its West Synchrony™? Prefillable Syringe (PFS) System at CPHI Worldwide in Frankfurt, Germany. This innovative system marks a significant shift in drug delivery solutions by offering a fully verified platform from a single supplier that will be commercially available in January 2026. The West Synchrony PFS system delivers a fully verified system-level solution designed specifically for biologics and vaccines. It sets a new standard in drug delivery by accelerating syringe selection through its comprehensive performance and regulatory data packages. Key benefits of the West Synchrony PFS system include: Design and System-Level Performance: a single design verification and characterization package from West ensures the form, fit and function of the entire PFS system. Regulatory Ease with Comprehensive Submission: a streamlined submission process with one system-level drug master file and regulatory package tailored for comprehensive regulatory needs. Single Source Supply: single supplier approach, offering make-to-stock and make-to-order supply with low minimum order quantities, ensuring reliability and flexibility. Reported Earnings • Oct 24
Third quarter 2025 earnings: EPS and revenues exceed analyst expectations Third quarter 2025 results: EPS: US$1.94 (up from US$1.87 in 3Q 2024). Revenue: US$804.6m (up 7.7% from 3Q 2024). Net income: US$140.0m (up 2.9% from 3Q 2024). Profit margin: 17% (in line with 3Q 2024). Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 10%. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Ankündigung • Oct 09
West Pharmaceutical Services, Inc. to Report Q3, 2025 Results on Oct 23, 2025 West Pharmaceutical Services, Inc. announced that they will report Q3, 2025 results Pre-Market on Oct 23, 2025 Ankündigung • Sep 12
West Pharmaceutical Services, Inc. Announces Departure of Kimberly Banks Mackay, Senior Vice President, General Counsel, and Corporate Secretary, Effective No Later Than December 31, 2025 On September 11, 2025, West Pharmaceutical Services, Inc. (the “Company”) announced that Kimberly Banks MacKay, Senior Vice President, General Counsel, and Corporate Secretary, will be leaving the Company. The Company and Ms. MacKay have agreed to discuss an appropriate transition period which will end no later than December 31, 2025, to ensure continuity and a smooth and orderly transition of responsibilities. Ms. MacKay will continue her current duties until she leaves the Company. The Company extends its gratitude to Ms. MacKay for her exemplary service and contributions during her tenure and wishes her success in her future endeavors. Declared Dividend • Aug 07
Dividend of US$0.22 announced Shareholders will receive a dividend of US$0.22. Ex-date: 12th November 2025 Payment date: 19th November 2025 Dividend yield will be 0.4%, which is about the same as the industry average. Payout Ratios Payout ratio: 12%. Cash payout ratio: 18%. Board Change • Aug 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 8 highly experienced directors. Director Janet Haugen was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 27
Second quarter 2025 earnings: EPS and revenues exceed analyst expectations Second quarter 2025 results: EPS: US$1.83 (up from US$1.53 in 2Q 2024). Revenue: US$766.5m (up 9.2% from 2Q 2024). Net income: US$131.8m (up 18% from 2Q 2024). Profit margin: 17% (up from 16% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 5.0%. Earnings per share (EPS) also surpassed analyst estimates by 18%. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 9% per year whereas the company’s share price has fallen by 8% per year. Price Target Changed • Jul 25
Price target increased by 11% to US$310 Up from US$279, the current price target is an average from 11 analysts. New target price is 18% above last closing price of US$264. Stock is down 7.5% over the past year. The company is forecast to post earnings per share of US$6.50 for next year compared to US$6.75 last year. Valuation Update With 7 Day Price Move • Jul 24
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to US$279, the stock trades at a forward P/E ratio of 43x. Average trailing P/E is 37x in the Life Sciences industry in the US. Total loss to shareholders of 17% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$286 per share. Upcoming Dividend • Jul 23
Upcoming dividend of US$0.21 per share Eligible shareholders must have bought the stock before 30 July 2025. Payment date: 06 August 2025. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of American dividend payers (4.5%). Lower than average of industry peers (0.6%). Ankündigung • Jul 22
West Pharmaceutical Services, Inc. Announces Appointment of Robert McMahon as Senior Vice President, Effective as of August 4, 2025 On July 21, 2025, West Pharmaceutical Services, Inc. Announced the appointment of Robert McMahon as Senior Vice President, effective as of August 4, 2025 (the “Commencement Date”). Mr. McMahon will serve on the Company's senior leadership team and will oversee finance, audit, treasury, tax, investor relations and procurement. Prior to joining West, Mr. McMahon, age 56, served as the Chief Financial Officer of Agilent Technologies Inc., a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. At Agilent, he was responsible for finance, audit, treasury, tax, investor relations, IT and procurement. From 2014 to 2018, Mr. McMahon served as Chief Financial Officer at Hologic, Inc., a developer, manufacturer and supplier of premium diagnostics products, medical imaging systems, and surgical products. Prior to Hologic, Mr. McMahon spent 20 years with Johnson & Johnson in various executive financial roles of increasing responsibility. He has also served as an Independent Director at OraSure Technologies, Inc. since 2023. Mr. McMahon earned his Master of Business Administration from the University of Central Florida and his Bachelor's degree from the University of Florida. Ankündigung • Jul 21
West Pharmaceutical Services, Inc. Announces CFO Changes, Effective August 4, 2025 West Pharmaceutical Services, Inc. announced the appointment of Robert McMahon as the company's new Chief Financial Officer (CFO), effective August 4, 2025. Mr. McMahon will succeed Bernard Birkett, CFO, who announced his intention to retire earlier this year. Mr. Birkett will assume the role of Senior Advisor to the CEO through the end of the year to ensure a seamless transition. Mr. McMahon has been Chief Financial Officer of Agilent Technologies Inc. since 2018. In this role, he is responsible for finance, audit, treasury, tax, investor relations, IT and procurement. Prior to Agilent, Mr. McMahon was the CFO at Hologic, Inc. and spent 20 years with Johnson & Johnson, in executive financial roles of increasing responsibility. He has also served as an Independent Director at OraSure Technologies, Inc. since 2023. Ankündigung • Jul 08
West Pharmaceutical Services, Inc. to Report Q2, 2025 Results on Jul 24, 2025 West Pharmaceutical Services, Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 24, 2025 Buy Or Sell Opportunity • Jun 17
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 5.4% to US$218. The fair value is estimated to be US$275, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 10%. For the next 3 years, revenue is forecast to grow by 5.6% per annum. Earnings are also forecast to grow by 11% per annum over the same time period. Declared Dividend • May 09
Dividend of US$0.21 announced Shareholders will receive a dividend of US$0.21. Ex-date: 30th July 2025 Payment date: 6th August 2025 Dividend yield will be 0.4%, which is about the same as the industry average. Payout Ratios Payout ratio: 13%. Cash payout ratio: 20%. Ankündigung • May 06
Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against West Pharmaceutical Services, Inc. and Certain of Its Executives Labaton Keller Sucharow LLP announces that, on May 5, 2025, it filed a securities class action lawsuit (Complaint) on behalf of its client the New England Teamsters Pension Fund (New England Teamsters) against West Pharmaceutical Services, Inc. (Company) and certain West executives (collectively, “Defendants”). The action, which is captioned New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., No. 25-cv-02285 (E.D. Pa.) asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder, on behalf of all persons and entities that purchased or otherwise acquired West common stock between February 16, 2023 and February 12, 2025, inclusive (the “Class Period”). West is a medical supplies company based in Exton, Pennsylvania that operates as a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. The Complaint alleges that, throughout the Class Period, Defendants failed to disclose that: (a) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin High-Value Products portfolio; (b) West’s SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to the Company’s profit margins due to operational inefficiencies; (c) these margin pressures created the risk of costly restructuring activities, including the Company’s exit from continuous glucose monitoring contracts with long-standing customers; and (d) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis. The truth about this fraud was revealed over a series of disclosures culminating on February 13, 2025, when West issued extremely weak 2025 revenue and earnings forecasts. West attributed the disappointing guidance in part to contract manufacturing headwinds, including the loss of two major continuing glucose monitoring customers that had begun transitioning to in-house manufacturing of next-generation devices after West “made the decision to not participate going forward as its financial thresholds cannot be achieved.” West also revealed that its SmartDose wearable injector devices would be “margin-dilutive” in 2025 and that it would be “taking steps to improve [its SmartDose] economics, and all options are on the table.” On this news, West’s stock dropped $123.17 per share, a decline of 38%, to close at $199.11 on February 13, 2025. Reported Earnings • Apr 25
First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2025 results: EPS: US$1.24 (down from US$1.57 in 1Q 2024). Revenue: US$698.0m (flat on 1Q 2024). Net income: US$89.8m (down 22% from 1Q 2024). Profit margin: 13% (down from 17% in 1Q 2024). Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates by 1.3%. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 12% per year. Ankündigung • Apr 24
West Pharmaceutical Services, Inc. Announces Management Changes On April 22, 2025, Mr. Bernard Birkett notified West Pharmaceutical Services, Inc. of his intention to retire as Senior Vice President later 2025. The Company has initiated a search for Mr. Birkett’s successor and is implementing a comprehensive transition plan. Mr. Birkett will continue in his current role, remaining with the Company until a successor is found to ensure an effective transition. Then he will assume an advisory role until December 31, 2025. On April 24, 2025, the Company announced that it had appointed Shane Campbell to serve as Senior Vice President, Chief Proprietary Segment Officer, effective May 5, 2025 (the "Commencement Date"). Mr. Campbell will serve on the Company's senior leadership team and will oversee the Proprietary Products segment. Mr. Campbell, 45, joins the Company from Carlisle Companies Inc., where he most recently served as Chief Commercial Officer of the Construction Materials business. As an accomplished leader, Mr. Campbell brings extensive global management experience across operations, engineering, commercial and strategy. Over a 20-year career at DuPont, Mr. Campbell served in several senior global leadership roles focused in the areas of elastomers, polymers, building materials, chemicals, packaging and safety. Mr. Campbell received his Master of Business Administration from Harvard Business School and his Bachelor of Mechanical Engineering from the University of Delaware. Upcoming Dividend • Apr 23
Upcoming dividend of US$0.21 per share Eligible shareholders must have bought the stock before 30 April 2025. Payment date: 07 May 2025. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of American dividend payers (5.1%). Lower than average of industry peers (0.7%). Ankündigung • Apr 10
West Pharmaceutical Services, Inc. to Report Q1, 2025 Results on Apr 24, 2025 West Pharmaceutical Services, Inc. announced that they will report Q1, 2025 results Pre-Market on Apr 24, 2025 Ankündigung • Mar 13
West Pharmaceutical Services, Inc., Annual General Meeting, May 06, 2025 West Pharmaceutical Services, Inc., Annual General Meeting, May 06, 2025. Ankündigung • Mar 12
West Pharmaceutical Services, Inc. Announces Executive Changes On March 7, 2025, West Pharmaceutical Services, Inc. announced that Cindy Reiss-Clark, Senior Vice President and Chief Commercial Officer, has departed the Company, effective the same day. As part of this transition, her leadership responsibilities will be managed on an interim basis by Aileen Kinsella, the Company's Head of Proprietary Product Sales. Declared Dividend • Feb 25
Dividend of US$0.21 announced Shareholders will receive a dividend of US$0.21. Ex-date: 30th April 2025 Payment date: 7th May 2025 Dividend yield will be 0.4%, which is about the same as the industry average. Payout Ratios Payout ratio: 12%. Cash payout ratio: 22%. Ankündigung • Feb 21
West Pharmaceutical Services, Inc. Announces Second Quarter 2025 Dividend, Payable on May 7, 2025 West Pharmaceutical Services, Inc. announced that the Company's Board of Directors has approved a second-quarter 2025 dividend of $0.21 per share. The dividend will be paid on May 7, 2025, to shareholders of record as of April 30, 2025. Price Target Changed • Feb 14
Price target decreased by 20% to US$306 Down from US$380, the current price target is an average from 10 analysts. New target price is 42% above last closing price of US$215. Stock is down 41% over the past year. The company is forecast to post earnings per share of US$5.99 for next year compared to US$6.75 last year. Ankündigung • Feb 14
West Pharmaceutical Services, Inc. Provides Earnings Guidance for the Full Year 2025 West Pharmaceutical Services, Inc. provided earnings guidance for the full year 2025. For the year, the Company anticipates net sales in a range of $2.875 billion to $2.905 billion. New Risk • Feb 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 3.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Feb 13
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: EPS: US$6.75 (down from US$7.99 in FY 2023). Revenue: US$2.89b (down 1.9% from FY 2023). Net income: US$492.7m (down 17% from FY 2023). Profit margin: 17% (down from 20% in FY 2023). The decrease in margin was primarily driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.9%. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings. Declared Dividend • Jan 31
Third quarter dividend of US$0.21 announced Shareholders will receive a dividend of US$0.21. Ex-date: 7th February 2025 Payment date: 11th February 2025 Dividend yield will be 0.2%, which is lower than the industry average of 0.4%. Payout Ratios Payout ratio: 12%. Cash payout ratio: 19%. Ankündigung • Jan 30
West Pharmaceutical Services, Inc. to Report Q4, 2024 Results on Feb 13, 2025 West Pharmaceutical Services, Inc. announced that they will report Q4, 2024 results Pre-Market on Feb 13, 2025 Ankündigung • Jan 29
West Pharmaceutical Services, Inc. Announces Dividend for the First-Quarter of 2025, Payable on February 11, 2025 West Pharmaceutical Services, Inc. announced that the Company's Board of Directors has approved a first-quarter 2025 dividend of $0.21 per share. The dividend will be paid on February 11, 2025, to shareholders of record as of February 7, 2025. Ankündigung • Jan 22
West Pharmaceutical Services, Inc. Introduces Daikyo PLASCAP RUV Closures in New Nested Format At Pharmapack West Pharmaceutical Services, Inc. announced the introduction of Daikyo PLASCAP Ready-to-Use Validated (RUV) closures in a new nested format available in multiple configurations at this year's Pharmapack event in Paris, France. This marks West's latest product offering supporting the needs of advanced therapies, one of the fastest growing areas, driven by continued innovation in cell and gene therapy treatments. The PLASCAP closure is a metal-free polypropylene cap with an integrated stopper. This one-step press-fit solution for vial closure is offered in ready-to-use, validated formats compatible with vials with 13mm and 20 mm crowns. The new 6x8 nested tub configuration supports the West 10ml nested CZ vials as well as selected nested vials with a 20mm crown. Ankündigung • Dec 11
West Pharmaceutical Services, Inc Elects Janet Haugen as New Director to the Board West Pharmaceutical Services, Inc. announced the Board of Directors has elected Janet Haugen as its newest member. With the addition of Ms. Haugen, West's Board has 12 directors. Ms. Haugen, 66, is the former Chief Financial Officer of Unisys Corporation, a role she served in for more than 16 years. During her 20-year tenure at Unisys, Ms. Haugen oversaw the business transformation from a mainframe hardware, software and maintenance company to an IT services and software provider. In addition to her core finance responsibilities, she had oversight of Unisys' corporate development, IT, procurement, facilities and legal functions. Prior to joining Unisys, Ms. Haugen was a partner at Ernst & Young working with Fortune 500 companies serving global clients in the technology and manufacturing industries.Ms. Haugen currently serves on the Board of Directors of Bentley Systems, Juniper Networks and CentralSquare Technologies. Ms. Haugen earned her degree in Economics from Rutgers University. In addition, she is a certified director of the National Association of Corporate Directors (NACD). Buy Or Sell Opportunity • Nov 20
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 3.7% to US$312. The fair value is estimated to be US$257, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 8.3%. For the next 3 years, revenue is forecast to grow by 6.9% per annum. Earnings are also forecast to grow by 13% per annum over the same time period. Declared Dividend • Oct 27
Third quarter dividend of US$0.21 announced Shareholders will receive a dividend of US$0.21. Ex-date: 13th November 2024 Payment date: 20th November 2024 Dividend yield will be 0.3%, which is about the same as the industry average. Payout Ratios Payout ratio: 12%. Cash payout ratio: 19%. Reported Earnings • Oct 24
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: EPS: US$1.87 (down from US$2.17 in 3Q 2023). Revenue: US$746.9m (flat on 3Q 2023). Net income: US$136.0m (down 16% from 3Q 2023). Profit margin: 18% (down from 22% in 3Q 2023). Revenue exceeded analyst estimates by 5.3%. Earnings per share (EPS) also surpassed analyst estimates by 27%. Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 8% per year and the company’s share price has also fallen by 8% per year. 
